

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

Prevalence and Risk of Birth Defects Observed in a Prospective Cohort Study;  
the Hokkaido Study on Environment and Children's Health

研究代表者 岸 玲子 北海道大学環境健康科学研究教育センター 特別招へい教授  
研究分担者 花岡 知之 北海道大学環境健康科学研究教育センター 客員教授  
研究分担者 水上 尚典 北海道大学大学院医学研究科  
生殖・発達医学講座産科・生殖医学分野 特任教授  
研究分担者 馬場 剛 札幌医科大学医学部産科周産期科・生殖内分泌科 講師  
研究分担者 千石 一雄 旭川医科大学医学部産婦人科学講座 教授  
研究分担者 有賀 正 北海道大学大学院医学研究科・小児科学分野 特任教授

**研究要旨**

**Background:** Prevalence rates of all anomalies classified into birth defects, including those identified before the 22th gestational week, are limited in published reports, including those from International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR). In our birth cohort study, we collected the data for all birth defects after 12 weeks of gestation.

**Methods:** Subjects in this study comprised 19,244 pregnant women who visited one of 37 associated hospitals in the Hokkaido Prefecture from 2003 to 2012, and completed follow-up. All birth defects after 12 weeks of gestation, including 55 marker anomalies associated with environmental chemical exposures, were recorded. We examined parental risk factors for birth defects, and the association between birth defects and risk of growth retardation.

**Results:** Prevalence of all birth defects was 18.9/1000 births. The proportion of birth defects identified between 12 and 22 weeks gestation was approximately 10% of all birth defects. Among congenital malformation of the nerve system, 39% were observed before 22 weeks of gestation. All anencephaly and encephalocele were identified before 22 weeks of gestation. We observed different patterns of parental risk factors between birth defect cases included in ISBDSR and cases not included. Cases included in ISBDSR were associated with an increased risk of preterm birth. Cases not increased in ISBDSR were associated with an increased risk of being small-for-gestational age at term.

**Conclusions:** Data from our study complemented the data from ICBDSR. We recommended that birth defects not included in ICBDSR also be analyzed to elucidate the etiology of birth defects.

**研究協力者**

伊藤 久美子  
(北海道大学大学院医学研究科  
社会医学講座公衆衛生学分野)  
田村菜穂美  
(北海道大学環境健康科学研究教育センター)

**A . 研究目的**

Birth defects, including malformations, deformations, and chromosomal abnormalities, are major causes of neonatal mortality.<sup>1,2</sup> Previously, it was believed that

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

most birth defects were idiopathic. However, it is now recognized that there are birth defects known to be caused by hazardous epidemics, such as thalidomide exposure during pregnancy. To investigate and prevent birth defects, surveillance programs affiliated with the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) are underway.<sup>3, 4</sup>

Incidence of birth defects cannot be accurately estimated because fetal death cases before diagnosis of the pregnancy are unknown. The Japan Association of Obstetricians and Gynaecologists (JAOG) reports observed birth defect cases via the nation-wide hospital-based monitoring program to the ICBDSR. However, mortality cases before 22 weeks of gestation have not been reported.<sup>3</sup> Data regarding the prevalence of all birth defects, and cases observed before 22 weeks of gestation, could be captured via prospective cohort studies of pregnant women. In this report, we described birth defects observed beginning at 12 weeks of gestation during the pre-natal care of pregnant women in a prefectural-wide hospital-based birth cohort study, the Hokkaido Study on Environmental and Children's Health.<sup>5, 6</sup> Furthermore, we examined parental risk factors for birth defects, and the association between the birth defects and the risk of growth retardation. We analyzed and presented the differences in these estimations between those birth defect cases included in the ICBDSR and those cases not included.

## B . 研究方法

### Study cohort

The primary goal of the Hokkaido Study on

Environmental and Children's Health was to examine the effects of perinatal environmental chemical exposures on birth outcomes, including birth defects. The details of this cohort study have been described previously.<sup>5, 6</sup> We enrolled women in early pregnancy (<13 weeks gestational age), who visited one of the 37 associated hospitals or clinics including 3 university hospitals and their associated clinics in the Hokkaido Prefecture, from February 2003 to March 2012. These hospitals and clinics are evenly distributed throughout the Hokkaido prefecture. We obtained written informed consent from all subjects. The institutional ethical board of the Hokkaido University Center for Environmental and Health Sciences (reference no.14, March 22, 2012), and Hokkaido University Graduate School of Medicine (May 31, 2003) approved the study protocol.

### Follow-up

Follow-up with the pregnant women enrolled in the study and their offspring is on-going. In this study, we used the dataset of the fixed cohort as of the end of 2015, which included 20,805 women. The number of study participants with a birth record was 19,579. The follow-up rate at birth was 94.1%. Data from 5.9% of participants were missing because the participants were lost-to-follow-up.

### Data collection

The number of subjects in this report who had birth outcome data and gestational week data was 19,244. According to the standardized manual provided by the principal investigator of the Hokkaido University (R.K.), each physician in charge of each woman in the delivery units of the participating hospitals or clinics ascertained and recorded birth defects within 7 days of

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

delivery or at the termination of pregnancy. The physicians selected from a list of 55 disease names to record the birth defect, or if the disease was not on the list, described disease names in the unified sheet. These 55 birth defects listed on the unified sheet are possible effect markers of environmental exposure. We encoded the birth defects according to the International Statistical Classification of Diseases and Related Health Problems (ICD), 10th revision.<sup>7</sup> The ICBDSR monitoring list that physicians also complete lists 35 malformations.<sup>3</sup>

Medical records of the parents and offspring at delivery or termination, including gestational age and birth weight, were also recorded on the same sheet. Preterm birth was defined as birth between 22 and 37 weeks of gestation. Very low birth weight (VLBW) was defined as birth weight <1500 g. Small for gestational age at term (term SGA) was defined as birth weight below the 10th percentile reference point for birth weight, according to gestational age, sex, and parity. We used the database of birth weight published by the Japan Pediatric Society as a reference.<sup>8</sup>

The baseline data regarding information on parental reproductive history and life style factors, including age at the entry of this study, body mass index before the pregnancy, parity, drinking habit in the first trimester, smoking during the pregnancy, and any usage of assisted reproductive technologies, were collected using a self-administered questionnaire.

### Statistical analysis

Differences between expected and observed frequencies by gestational week (before week 22 or from week 22 of gestation), sex (males or females), and the number of births (singletons or multiples) for each category

or defect were tested by the Fisher's exact test.

We calculated risk ratios (RRs) for all kinds of birth defects, and birth defects included or not included in the ICBDSR, in singleton fetus or infants, according to maternal and paternal factors, including maternal age at the entry (<35, ≥35 years old), maternal body mass index, parity (0, ≥1), assisted reproductive technology (used, unused), age of the partner at the entry (<35, ≥35 years old), maternal alcohol use in early period of the pregnancy (used, unused), and maternal smoking during pregnancy (smoking, nonsmoking). We estimated RRs of birth defects by preterm birth, VLBW, and term SGA. We calculated RRs using log-binomial regression analysis with and without adjustment for the above maternal and paternal factors. P value <0.05 was considered as statistically significant. Statistical analyses were calculated using Stata 14 (Stata Corp, College Station, TX, USA).

### C . 研究結果

We show the distribution of mother and singleton child pairs according to the gestational week and birth outcomes in Figure 1. Women who delivered between 12 and 21 weeks of gestation accounted for 10.0% of all births. The proportion of birth defects among deliveries at 12-21 weeks was 9.7% (32/341) of all birth defect cases observed in this report. Consequently, prevalence of birth defects in this period was approximately ten times as high as the birth defects observed from 22 weeks of gestation. Among study subjects, 40 cases ended in termination and 18 of the 40 cases had a birth defect. Of 149 cases of miscarriage among study subjects, 15 of the cases had a

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

birth defect and of 57 stillbirths, 4 had a birth defect. Of the 18,565 cases that were live born, 277 had a birth defect.

The prevalence of birth defects classified by major ICD-10 categories according to gestational week, sex and number of births is shown in Table 1. Each defect was counted separately, even if there were accompanying defects in the same infant. The prevalence of all birth defects observed in this study was 18.9/1,000 births (19.7/1000 pregnant women). The highest prevalence was observed in malformations or deformations of the musculoskeletal system (4.1/1,000 births), followed by malformations of the circulatory system (3.6/1,000 births). The prevalence of the birth defects from 22 weeks of gestation was 17.4/1,000 births. The prevalence before 22 weeks of gestation was 164.2/1,000 births ( $P < 0.0001$ ). Prevalence of malformations of the nervous system, malformations of eye or ear or face or neck, malformations of the urinary system, malformations and deformations of the musculoskeletal system, and Chromosomal abnormalities was higher before 22 weeks of gestation compared to after 22 weeks of gestation. Among the congenital malformation of the nerve system, 39% were observed before 22 weeks of gestation. The total prevalence was not significantly different between males and females; 19.6/1,000 births in males and 17.6/1,000 births in females ( $P = 0.48$ ). Malformations of eye or ear or face or neck, and the circulatory system were found more in females than males, but the differences were not statistically significant ( $P = 0.07$  and  $0.18$ , respectively). Malformations of genital organs and urinary system occurred significantly more in males than females ( $P < 0.001$  and  $P = 0.003$ , respectively). The

total prevalence was not significantly different between singleton (18.9/1,000 births) and multiple birth infants (20.8/1,000) ( $P = 0.70$ ). In multiple births, triplet births occurred only in nine pregnancies. No birth defects were observed in the triplet births. Most birth defect cases were identified before birth. All cases of malformation of the nervous system, digestive system except for oral cavity, and genital organs were identified before birth. Malformations of the respiratory system showed the lowest percentage of identification before birth (50.0%).

There were 32 cases of multiple defects. The most frequent combination of multiple defects was malformations of the circulatory system and chromosomal abnormalities (n, 8), followed by malformations of the circulatory system and other malformations (n, 5), and cleft lip/cleft palate and malformations and deformations of the musculoskeletal system (n, 5).

The prevalence of selective birth defects included in the ICBDSR is shown in Table 2. The prevalence of birth defects included in the ICBDSR was 8.4/1,000 births. Cleft lip with or without cleft palate showed the highest prevalence (1.3/1,000 births), followed by Down syndrome (1.0/1,000 births) and polydactyly (1.0/1,000 births). The prevalence of the birth defects from 22 weeks of gestation was 7.8/1,000 births. The prevalence before 22 weeks of gestation was 64.7/1,000 births. All anencephaly and encephalocele cases were observed before 22 weeks of gestation. Among the spina bifida cases, 33% were observed before 22 weeks of gestation. Most cases were identified before birth. Limb reduction defects showed the lowest percentage of identification before birth

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

(75.0%).

RRs of birth defects in singletons for selective maternal and paternal factors are shown in Table 3. For those birth defects included in the ICBDSR, maternal age $\geq$ 35 significantly increased birth defect risk (adjusted RR, 1.89; 95% CI, 1.23-2.91). For birth defects not included in the ICBDSR, nulliparous and assisted reproductive technology significantly increased birth defect risk (adjusted RR, 1.63; 95% CI, 1.13-2.32, adjusted RR, 1.99; 95% CI, 1.06-1.41, respectively). Body mass index, age of partner, alcohol use, and smoking did not significantly increase birth defect risk.

RRs of growth retardation in singletons with birth defects are shown in Table 4. Presence of a birth defect significantly increased the adjusted RRs of VLBW both for birth defects included and those not included in the ICBDSR. For birth defects included in the ICBDSR, presence of a birth defect significantly increased the adjusted RRs of preterm birth (adjusted RR, 2.20; 95% CI, 1.34-3.60). Among birth defects not included in the ICBDSR, significantly increased RRs of term SGA was observed (adjusted RR, 2.01; 95% CI, 1.11-3.66). Birth defects presented in Table 3 and Table 4 include those observed before 22 weeks of gestation.

#### D . 考察

The JAOG system is an important nation-wide monitoring system for assessing incidence and prevalence of birth defects, and identifying outbreaks that has been in place for approximately 40 years. However, the system aggregates birth defect cases. It is not a population-based registration system, such as those in Scandinavian countries, but a hospital-based monitoring system. The

primary difference between the nation-wide reporting of birth defect cases by JAOG and the present study is that our study is a prospective birth cohort study, in which various data covering all gestational periods, many parental factors, and other related observations, such as infant development after entry to the cohort were collected, thereby providing additional research and reporting opportunities. In our study, we identified the prevalence of all birth defects after 12 weeks of gestation among the general population of Japanese women in a prefectural-wide prospective cohort study. Our study included 55 birth defects as possible effect markers of environment exposure. We reported that the character of those birth defects not included in the ICBDSR was different from those included in the ICBDSR.

In our study, we were able to examine the above issues because we obtained informed written consent from all women at the time of notification of their pregnancy, or before 13 weeks of gestation. However, we could not include women who miscarried for any reason or cause before the informed consent was obtained. If lethal defects occurred during conception, or before the entry of epidemiological studies or surveillance programs, valid incident cases could not be counted. Because an accurate denominator, i.e. number of fetuses at risk, is unknown, this study omitted observations before 12 weeks of gestation. The ICBDSR surveillance programs omit observations before 22 weeks of gestation. Observation before 22 weeks of gestation are included in this report.

The Japanese data reported in the ICBDSR showed that the prevalence of birth defects (total number of cases among live

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

births, stillbirths, and elective terminations of pregnancy for a fetal anomaly) was 1.6% per year during 2007 - 2011.<sup>3</sup> Using the same denominator and numerator, the prevalence of birth defects included in the ICBDSR was found to be 0.8% in our study. The prevalence in our study is lower than that reported in the nation-wide hospital-based monitoring project. One possibility is that the ICBDSR monitoring project consists of core hospitals in each area, such as university hospitals and specified children's hospitals, for example, the Hokkaido Medical Centers for Child Health and Rehabilitation. High-risk pregnant women might tend to visit such hospitals, and severe birth defect cases are usually transferred to such core hospitals before delivery. Moreover, only 10 institutions participated in the monitoring project in the Hokkaido area. Our 37 associated hospitals or clinics including 3 university hospitals, were evenly distributed throughout the Hokkaido prefecture, and accounted for approximately 40 % of the institutes with delivery units in this prefecture.<sup>9</sup> Therefore, we guess that our study participant represented the population of women in general in the Hokkaido area. Another possibility might be that our participants were relatively healthy pregnant women who had an interest in environment and health in communities.

We found that birth defects observed before 22 weeks of gestation was approximately 10% of all birth defects. However, the proportion of birth defects in this early gestational period was very high. Therefore, this finding confirmed a large proportion of stillbirths and terminations were caused by birth defects. Pregnancies with major structural defects tend to be

terminated. Information on termination of pregnancy is difficult to obtain in general; however, prospective birth cohort studies provide an opportunity to obtain information on termination.

Regarding differences by sex, a population-based study in the US observed that the overall prevalence of major defects in live births was 3.9% among males and 2.8% among females during 1968 to 1995.<sup>10</sup> We did not observe significant differences in prevalence between males and females. Higher prevalence of malformations of genital organs and urinary system in males, and malformations of ear, face, and neck in females were consistent with data in the US. However, we found a difference regarding malformations of the circulatory system; prevalence was higher in females in our study. The mechanisms of a sex-based difference in prevalence are unknown. However, race-based difference in prevalence suggests involvement of differences in susceptibility genes.<sup>11</sup>

Concerning multiple gestations, the total prevalence of birth defects was not different between singleton and multiple infants in this study. However, there were congenital malformations observed only in twins. Additional etiological factors appeared to be a factor in multiple births.<sup>12</sup> Although the prevalence is low, a study of multiple births would be necessary to elucidate the cause of birth defects.

Our study findings suggest a different pattern of parental risk factors between those birth defects included in the ISBDSR, and those not included. Various risk factors for birth defects have been suggested, including environmental exposures.<sup>11, 13</sup> However, the causes of most birth defects remain unknown. The

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

increased risk from high maternal age in our study was consistent with previous studies.<sup>14</sup> In previous studies, there was less evidence that high paternal age affected risk.<sup>15</sup> We observed increased risk due to high age of the partner in birth defects included in the ICBDSR, although the RR was not statistically significant. Increased risk due to usage of assisted reproductive technologies of birth defects not included in the ICBDSR was comparable finding to previous studies.<sup>16</sup> The risk of alcohol use and smoking has been reported in previous studies; however, we did not observe the significant risk.<sup>17, 18</sup> Future studies need to further examine parental and environmental factors, including passive smoking,<sup>19</sup> endocrine disrupting chemicals,<sup>20</sup> indoor air pollution,<sup>21</sup> folate,<sup>22, 23</sup> supplemental vitamins,<sup>24-26</sup> and stress.<sup>27, 28</sup>

It was indicated in a previous study that structural birth defects contributed to a substantial proportion of preterm birth.<sup>29</sup> We observed an increased risk of preterm birth in birth defects included in the ICBDSR. In contrast, we observed an increased risk of term SGA in birth defects not included in the ICBDSR. Both preterm birth and term SGA are indicators of fetal growth retardation, however, their etiological factors might be difference (Tamura N., et al., in submission). Therefore, our findings might suggest that there were different etiological factors between birth defects included and those not included in the ICBDSR. Our observation of birth defects not included in the ICBDSR also suggest that the same etiology might be involved in both fetal growth and in birth defects, such as usage of assisted reproductive technologies. Because of future morbidity of children associated with

growth retardation,<sup>30, 31</sup> our findings emphasize that prospective birth cohort studies play an important role in the prevention of childhood illness.

Birth defects are rare outcomes. In addition, it is often not possible to conduct prospective studies for the investigation of birth defects. Therefore, researchers usually select a case-control study design, which is appropriate for rare disease outcomes, in order to elucidate the relationship between birth defects and parental and environmental factors. However, in case-control studies, an underlying recall bias of exposure is not avoidable.<sup>11</sup> Although the rarity of specific anomalies often limits the design of epidemiologic studies, the data from prospective studies are still valuable.

The potential disadvantages of our study data should be considered. The findings concerning the lost-to-follow-up group suggest the existence of 'bias due to withdrawal', although the reason for dropout was speculative. Participants from certain backgrounds might tend to withdraw from this or similar studies. However, the effect of the withdrawal was considered to be small because our follow-up rate was sufficiently high.

Malformations, deformations, and chromosomal abnormalities were previously thought to be idiopathic; therefore, they were frequently termed congenital anomalies. However, more recent research indicates that such abnormalities have been caused in part by parental conditions and environmental factors, such as drug usage and environmental pollution. The term 'congenital anomalies' is no longer used as the general term.<sup>13</sup> In this study, the term 'birth defects' was used.

Previously, observation of birth

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

defects began at birth. However, timing of ascertainment has begun earlier as technology advance, especially through the use of ultrasound.<sup>11</sup> In our study, most birth defects were diagnosed before birth. However, some birth defects, such as malformations of the respiratory system, showed low percentage of ascertainment before birth. We continue to collect data regarding birth defects using a self-administered questionnaire administered at 1, 2, 3, 4, and 7 years after delivery. Because there are birth defects that may not be identified until the later years of follow-up, it is anticipated that the number of birth defect cases will increase over time. Future studies investigating the association of risk factors with birth defects and the long-term impacts of birth defects, using the existing and future data of this cohort study, will provide valuable insights.

In conclusion, we reported the prevalence of birth defects in the general population of Japanese women in our cohort study. Although the monitoring system based on the ICBDSR is an excellent nation-wide monitoring system to survey longitudinal trend, the birth defects not included in the ICBDSR should also be analyzed to elucidate the etiology of birth defects. Prospective studies will contribute the elucidation of the prevalence and etiology of birth defects by using the framework of epidemiology.

## F . 研究発表

該当なし

## G . 知的財産権の出願・登録状況（予定を含む。）

該当なし

## 参考文献

1. Mathews TJ, MacDorman MF. Infant mortality statistics from the 2005 period linked birth/infant death data set. *Natl Vital Stat Rep.* 2008;57:1-32.
2. Statistics and Information Department Ministry of Health Labour and Welfare. *Vital Statistics of Japan, 2012.* Tokyo, Japan. Health Labour and Welfare Statistics Association; 2012.
3. The Centre of the International Clearinghouse for Birth Defects Surveillance and Research. *Annual Report 2014.* Roma, Italy. The Centre of the International Clearinghouse for Birth Defects Surveillance and Research; 2014.
4. Orioli IM, Amar E, Bakker MK, Bermejo-Sanchez E, Bianchi F, Canfield MA, et al. Cyclopia: an epidemiologic study in a large dataset from the International Clearinghouse of Birth Defects Surveillance and Research. *Am J Med Genet C Semin Med Genet.* 2011;157C:344-57.
5. Kishi R, Sasaki S, Yoshioka E, Yuasa M, Sata F, Saijo Y, et al. Cohort profile: the Hokkaido study on environment and children's health in Japan. *Int J Epidemiol.* 2011;40:611-8.
6. Kishi R, Kobayashi S, Ikeno T, Araki A, Miyashita C, Itoh S, et al. Ten years of progress in the Hokkaido birth cohort study on environment and children's health: cohort profile--updated 2013. *Environ Health Prev Med.* 2013;18:429-50.
7. World Health Organization. *ICD-10: International statistical classification of diseases and health related problems.* Geneva. World Health Organization; 1992.
8. Itabashi K, Fujimura M, Kusuda S, Tamura M, Hayashi T, Takahashi T, et al. The introduction of new standard values of birth weight according to gestational age (in Japanese). *J Jpn Pediatr Soc.* 2010;114:1271-93.
9. Hokkaido prefecture. *Hokkaido prefecture Medical Plan (in Japanese).* Sapporo, Japan. Hokkaido Prefecture; 2015.
10. Lary JM, Paulozzi LJ. Sex differences in the



厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

- prevalence of human birth defects: a population-based study. *Teratology*. 2001;64:237-51.
11. Werler M. Birth defects. In: Buck Louis GM, Platt RW, editors. *Reproductive and perinatal epidemiology*. NY: Oxford University Press; 2011. p. 186-203.
12. Christensen K. The 20th century Danish facial cleft population--epidemiological and genetic-epidemiological studies. *Cleft Palate Craniofac J*. 1999;36:96-104.
13. Wilcox AJ. *Fertility and pregnancy*. NY: Oxford University Press; 2010.
14. Hollier LM, Leveno KJ, Kelly MA, DD MC, Cunningham FG. Maternal age and malformations in singleton births. *Obstet Gynecol*. 2000;96:701-6.
15. Kazaura M, Lie RT, Skjaerven R. Paternal age and the risk of birth defects in Norway. *Ann Epidemiol*. 2004;14:566-70.
16. Boulet SL, Kirby RS, Reefhuis J, Zhang Y, Sunderam S, Cohen B, et al. Assisted Reproductive Technology and Birth Defects Among Liveborn Infants in Florida, Massachusetts, and Michigan, 2000-2010. *JAMA Pediatr*. 2016;170:e154934.
17. Gupta KK, Gupta VK, Shirasaka T. An Update on Fetal Alcohol Syndrome-Pathogenesis, Risks, and Treatment. *Alcohol Clin Exp Res*. 2016;40:1594-602.
18. Little J, Cardy A, Munger RG. Tobacco smoking and oral clefts: a meta-analysis. *Bull World Health Organ*. 2004;82:213-8.
19. Hoyt AT, Canfield MA, Romitti PA, Botto LD, Anderka MT, Krikov SV, et al. Associations between maternal periconceptional exposure to secondhand tobacco smoke and major birth defects. *Am J Obstet Gynecol*. 2016.
20. Winston JJ, Emch M, Meyer RE, Langlois P, Weyer P, Mosley B, et al. Hypospadias and maternal exposure to atrazine via drinking water in the National Birth Defects Prevention study. *Environ Health*. 2016;15:76.
21. Liu Y, Wang B, Li Z, Zhang L, Liu J, Ren A. Indoor air pollution and the risk of orofacial clefts in a rural population in Shanxi province, China. *Birth Defects Res A Clin Mol Teratol*. 2016;106:708-15.
22. Botto LD, Moore CA, Khoury MJ, Erickson JD. Neural-tube defects. *N Engl J Med*. 1999;341:1509-19.
23. Wilcox AJ, Lie RT, Solvoll K, Taylor J, McConnaughey DR, Abyholm F, et al. Folic acid supplements and risk of facial clefts: national population based case-control study. *BMJ*. 2007;334:464.
24. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and risk of birth defects. *Am J Epidemiol*. 1999;150:675-82.
25. Azais-Braesco V, Pascal G. Vitamin A in pregnancy: requirements and safety limits. *Am J Clin Nutr*. 2000;71:1325S-33S.
26. Johansen AM, Lie RT, Wilcox AJ, Andersen LF, Drevon CA. Maternal dietary intake of vitamin A and risk of orofacial clefts: a population-based case-control study in Norway. *Am J Epidemiol*. 2008;167:1164-70.
27. Carmichael SL, Shaw GM, Yang W, Abrams B, Lammer EJ. Maternal stressful life events and risks of birth defects. *Epidemiology*. 2007;18:356-61.
28. Hansen D, Lou HC, Olsen J. Serious life events and congenital malformations: a national study with complete follow-up. *Lancet*. 2000;356:875-80.
29. Shaw GM, Savitz DA, Nelson V, Thorp JM, Jr. Role of structural birth defects in preterm delivery. *Paediatr Perinat Epidemiol*. 2001;15:106-9.
30. Hack M, Taylor HG, Klein N, Eiben R, Schatschneider C, Mercuri-Minich N. School-age outcomes in children with birth weights under 750 g. *N Engl J Med*.

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

1994;331:753-9.

31. Tanabe K, Tamakoshi K, Kikuchi S, Murotsuki

J. Learning disability in 10- to 16-year-old  
adolescents with very low birth weight in Japan.

Tohoku J Exp Med. 2014;232:27-33.

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書




Figure 1. Subjects in this report, and the distribution of birth defects according to the gestational week and pregnancy outcomes.

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

Table 1. Prevalence of birth defects by major ICD-10 categories according to gestational age, sex, and multiple birth observed after 12th gestational week in the Hokkaido Study on Environment and Children's Health<sup>a</sup>

Classification (ICD-10 code)	Total (n = 19,195) n (/1,000 births)	Gestational week		Sex		Multiple birth		Ascertainment before birth (n = 19,195)
		12 - 21 week (n = 201) n (/1,000 births ≤ 21 week)	22 - 42 week (n = 18,994) n (/1,000 births ≥ 22 week)	males (n = 9,660) n (/1,000 male births)	females (n = 9,437) n (/1,000 female births)	singleton births (n = 18,811) n (/1,000 singleton births)	multiple births (n = 384) n (/1,000 multiple births)	
Congenital malformations of the nervous system (Q00-Q07)	18 ( 0.9 )	7 ( 34.8 )	11 ( 0.6 )	7 ( 0.7 )	8 ( 0.9 )	18 ( 1.0 )	0 ( 0.0 )	100
Congenital malformations of eye, ear, face, and neck (Q10-Q18)	30 ( 1.6 )	3 ( 14.9 )	27 ( 1.4 )	10 ( 1.0 )	20 ( 2.1 )	30 ( 1.6 )	0 ( 0.0 )	73.3
Congenital malformations of the circulatory system (Q20-Q28)	69 ( 3.6 )	0 ( 0.0 )	69 ( 3.6 )	29 ( 3.0 )	40 ( 4.2 )	68 ( 3.6 )	1 ( 2.6 )	85.5
Congenital malformations of the respiratory system (Q30-Q34)	2 ( 0.1 )	0 ( 0.0 )	2 ( 0.1 )	1 ( 0.1 )	1 ( 0.1 )	2 ( 0.1 )	0 ( 0.0 )	50.0
Cleft lip and cleft palate (Q35-Q37)	36 ( 1.9 )	0 ( 0.0 )	36 ( 1.9 )	19 ( 2.0 )	17 ( 1.8 )	35 ( 1.9 )	1 ( 2.6 )	88.9
Other congenital malformations of the digestive system (Q38-Q45)	19 ( 1.0 )	0 ( 0.0 )	19 ( 1.0 )	12 ( 1.2 )	7 ( 0.7 )	18 ( 1.0 )	1 ( 2.6 )	100
Congenital malformations of genital organs (Q50-Q56)	24 ( 1.3 )	0 ( 0.0 )	24 ( 1.3 )	21 ( 2.2 )	3 ( 0.3 )	23 ( 1.2 )	1 ( 2.6 )	100
Congenital malformations of the urinary system (Q60-Q64)	26 ( 1.4 )	2 ( 10.0 )	24 ( 1.3 )	21 ( 2.2 )	5 ( 0.5 )	22 ( 1.2 )	4 ( 10.4 )	96.2
Congenital malformations and deformations of the musculoskeletal system (Q65-Q79)	79 ( 4.1 )	9 ( 44.8 )	70 ( 3.7 )	43 ( 4.5 )	34 ( 3.6 )	79 ( 4.2 )	0 ( 0.0 )	88.6
Other congenital malformations (Q80-Q89)	28 ( 1.5 )	1 ( 5.0 )	27 ( 1.4 )	12 ( 1.2 )	16 ( 1.7 )	28 ( 1.5 )	0 ( 0.0 )	85.7
Chromosomal abnormalities, not elsewhere classified (Q90-Q99)	32 ( 1.7 )	11 ( 54.7 )	21 ( 1.1 )	14 ( 1.5 )	15 ( 1.6 )	32 ( 1.7 )	0 ( 0.0 )	90.6
Total	363 ( 18.9 )	33 ( 164.2 )	330 ( 17.4 )	189 ( 19.6 )	166 ( 17.6 )	355 ( 18.9 )	8 ( 20.8 )	

ICD, International Statistical Classification of Diseases and Related Health Problems 10th revision.

<sup>a</sup>Each defect was counted separately, even if there were accompanying defects in the same infant.

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

**Table 2. Prevalence of selected birth defects included in the ICBDSR surveillance program according to gestational age, observed after 12th gestational age in the Hokkaido Study on Environment and Children's Health<sup>a</sup>**

Birth defects	ICD-10 code	Total		Gestational week				Ascertainment before birth (n = 19,195) (%)
		(n = 19,195)		12 - 21 week		22 - 42 week		
		n	(/10,000 births)	n	(/10,000 births<22)	n	(/10,000 births≥22)	
Anencephaly	Q00	4	( 2.1 )	4	( 20.0 )	0	( 0.0 )	100
Spina bifida	Q05	3	( 1.6 )	1	( 49.8 )	2	( 1.1 )	100
Encephalocele	Q01	1	( 0.5 )	1	( 49.8 )	0	( 0.5 )	100
Microcephaly	Q02	1	( 0.5 )	0	( 0.0 )	1	( 0.5 )	100
Holoprosencephaly	Q04.2	2	( 1.0 )	0	( 0.0 )	2	( 1.1 )	100
Hydrocephaly	Q03	2	( 1.0 )	0	( 0.0 )	2	( 1.1 )	100
Anophthalmos/micropthalmos	Q11.0–Q11.2	0	( 0.0 )	0	( 0.0 )	0	( 0.0 )	
Anotia/microtia	Q16.0, Q16.1	2	( 1.0 )	0	( 0.0 )	2	( 1.1 )	100
Transposition of great vessels	Q20.1–Q20.3	6	( 3.1 )	0	( 0.0 )	6	( 3.2 )	100
Tetralogy of Fallot	Q21.3	5	( 2.6 )	0	( 0.0 )	5	( 2.6 )	60
Hypoplastic left heart syndrome	Q23.4	2	( 1.0 )	0	( 0.0 )	2	( 1.1 )	100
Coarctation of the aorta	Q25.1	3	( 1.6 )	0	( 0.0 )	3	( 1.6 )	100
Choanal atresia, bilateral	Q30.0	0	( 0.0 )	0	( 0.0 )	0	( 0.0 )	
Cleft palate without cleft lip	Q35	11	( 5.7 )	0	( 0.0 )	11	( 5.8 )	81.8
Cleft lip with or without cleft palate	Q36, Q37	25	( 13.0 )	0	( 0.0 )	25	( 13.2 )	92
Oesophageal atresia/stenosis	Q39.0–Q39.4	2	( 1.0 )	0	( 0.0 )	2	( 1.1 )	100
Small intestine atresia/stenosis	Q41	7	( 3.6 )	0	( 0.0 )	7	( 3.7 )	100
Anorectal atresia/stenosis	Q42	6	( 3.1 )	0	( 0.0 )	6	( 3.2 )	100
Undescended testicles	Q53	14	( 7.3 )	0	( 0.0 )	14	( 7.4 )	100
Hypospadias	Q54	8	( 4.2 )	0	( 0.0 )	8	( 4.2 )	100
Indeterminate sex	Q56.4	1	( 0.5 )	0	( 0.0 )	1	( 0.5 )	100
Renal agenesis	Q60	0	( 0.0 )	0	( 0.0 )	0	( 0.0 )	
Cystic kidney	Q61.1–Q61.3	2	( 1.0 )	0	( 0.0 )	2	( 1.1 )	100
Epispadias	Q64.0	0	( 1.0 )	0	( 0.0 )	0	( 1.0 )	
Bladder exstrophy	Q64.1	1	( 0.5 )	0	( 0.0 )	1	( 0.5 )	100
Polydactyly, preaxial	Q69	20	( 10.4 )	1	( 49.8 )	19	( 10.0 )	90
Limb reduction defects	Q71, Q72, Q73	4	( 2.1 )	1	( 49.8 )	3	( 1.6 )	75
Diaphragmatic hernia	Q79.0–Q79.1	5	( 2.6 )	0	( 0.0 )	5	( 2.6 )	100
Omphalocele	Q79.2	0	( 0.0 )	0	( 0.0 )	0	( 0.0 )	
Gastroschisis	Q79.3	0	( 0.0 )	0	( 0.0 )	0	( 0.0 )	
Prune belly sequence	Q79.4	0	( 0.0 )	0	( 0.0 )	0	( 0.0 )	
Trisomy 13	Q91.4–Q91.7	1	( 0.5 )	0	( 0.0 )	1	( 0.5 )	100
Trisomy 18	Q91.0–Q91.3	4	( 2.1 )	1	( 49.8 )	3	( 1.6 )	100
Down syndrome	Q90	20	( 10.4 )	4	( 20.0 )	16	( 8.4 )	90
Total		162	( 84.4 )	13	( 646.8 )	149	( 78.4 )	

ICD, International Statistical Classification of Diseases and Related Health Problems, 10th Revision; WHO, ICBDSR: International Clearinghouse for Birth Defects Surveillance and Research.

<sup>a</sup>Each defect was counted separately, even if there were accompanying defects in the same fetus.

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

Table 3. Risk ratios of birth defects in singleton infants according to maternal factors, observed in the Hokkaido Study on Environment and Children's Health

	Risk for all birth defects				Risk for Birth defects included in the ICBDSR program				Risk for birth defects not included in the ICBDSR program			
	without birth defects	with birth defects	Crude RR (95% CI)	Adjusted RR <sup>a</sup> (95% CI)	without birth defects <sup>b</sup>	with birth defects	Crude RR (95% CI)	Adjusted RR <sup>b</sup> (95% CI)	without birth defects <sup>b</sup>	with birth defects	Crude RR (95% CI)	Adjusted RR <sup>b</sup> (95% CI)
Age at the entry												
< 35 years old	15,196	243	1.00		15,195	106	1.00		15,195	138	1.00	
≥ 35 years old	3,301	71	1.34 (1.03, 1.74)	1.61 (1.19, 2.19)	3,301	38	1.64 (1.14, 2.38)	1.89 (1.23, 2.91)	3,301	33	1.10 (0.74, 1.60)	1.40 (0.90, 2.16)
Body mass index												
≥ 18	15,535	239	1.00		15,535	113	1.00		15,535	127	1.00	
< 18	1,905	33	1.12 (0.78, 1.61)	1.21 (0.82, 1.778)	1,905	11	0.80 (0.43, 1.47)	0.83 (0.42, 1.65)	1,905	22	1.41 (0.89, 2.20)	1.52 (0.94, 2.45)
Parity												
≥ 1	11,402	191	1.00		11,401	98	1.00		11,401	94	1.00	
0	7,095	123	1.03 (0.83, 1.29)	1.23 (0.94, 1.60)	7,095	46	0.76 (0.53, 1.07)	0.86 (0.57, 1.30)	7,095	77	1.31 (0.97, 1.77)	1.63 (1.13, 2.32)
Assisted reproductive technologies												
No	16,972	254	1.00		16,971	116	1.00		16,971	139	1.00	
Yes	743	21	1.86 (1.20, 2.89)	1.95 (1.23, 3.10)	743	9	1.76 (0.90, 3.46)	1.96 (0.97, 3.93)	743	12	1.96 (1.09, 3.51)	1.99 (1.06, 3.41)
Age of the partner												
< 35 years old	12,302	192	1.00		12,302	82	1.00		12,302	110	1.00	
≥ 35 years old	6,194	122	1.26 (1.00, 1.57)	1.09 (0.83, 1.43)	6,194	62	1.50 (1.08, 2.08)	1.26 (0.84, 1.87)	6,194	61	1.10 (0.81, 1.50)	0.97 (0.67, 1.39)
Alcohol use in early period of the pregnancy												
No	15,246	228	1.00		15,245	104	1.00		15,245	125	1.00	
Yes	2,141	38	1.18 (0.84, 1.66)	1.14 (0.80, 1.66)	2,141	17	1.16 (0.70, 1.94)	1.14 (0.65, 2.01)	2,141	21	1.19 (0.75, 1.89)	1.15 (0.70, 1.89)
Smoking during pregnancy												
No	12,766	210	1.00		12,766	98	1.00		12,766	112	1.00	
Yes	2,078	30	0.88 (0.60, 1.29)	0.99 (0.67, 1.45)	2,078	10	0.63 (0.33, 1.20)	0.69 (0.36, 1.33)	2,078	20	1.10 (0.68, 1.76)	1.26 (0.80, 2.04)

RR, risk ratio; CI, confidence interval

<sup>a</sup>Adjusted for maternal age, parity, maternal body mass index, and assisted reproductive technology.

<sup>b</sup>Excluding birth defect cases not listed in the ICBDSR surveillance program.

<sup>c</sup>Excluding birth defect cases listed in the ICBDSR surveillance program.

厚生労働科学研究費補助金（化学物質リスク研究事業）  
分担研究報告書

Table 4. Risk ratios of birth outcomes in singleton infants according to birth defects, observed in the Hokkaido Study on Environment and Children's Health

	Risk of birth defects				Risk of birth defects included in the ICBDSR program				Risk of birth defects not included in the ICBDSR program			
	without birth defects	with birth defects	Crude RR (95% CI)	Adjusted RR <sup>a</sup> (95% CI)	without birth defects <sup>b</sup>	with birth defects	Crude RR (95% CI)	Adjusted RR <sup>a</sup> (95% CI)	without birth defects <sup>c</sup>	with birth defects	Crude RR (95% CI)	Adjusted RR <sup>a</sup> (95% CI)
Preterm birth												
(-)	17,591	289	1.00		17,590	128	1.00		17,590	162	1.00	
(+)	895	25	1.64 (1.12, 2.40)	1.67 (1.13, 2.48)	895	16	2.29 (1.44, 3.66)	2.20 (1.34, 3.60)	895	9	1.09 (0.57, 2.06)	1.21 (0.64, 2.29)
Very low birth weight												
(-)	18,215	277	1.00		18,214	129	1.00		18,214	149	1.00	
(+)	231	33	8.50 (6.01, 12.0)	9.35 (6.57, 13.3)	231	13	7.31 (4.29, 12.5)	8.16 (4.81, 13.8)	231	20	9.45 (6.14, 14.5)	10.20 (6.59, 15.9)
Term small for gestational age												
(-)	15,924	664	1.00		15,919	97	1.00		15,919	117	1.00	
(+)	213	17	1.85 (1.16, 2.93)	1.91 (1.20, 3.03)	664	7	1.68 (0.82, 3.45)	1.75 (0.86, 3.59)	664	10	1.97 (1.08, 3.58)	2.01 (1.11, 3.66)

RR, risk ratio; CI, confidence interval.

<sup>a</sup> Adjusted for maternal age, parity, maternal body mass index, and assisted reproductive technology

<sup>b</sup> Excluding birth defect cases not listed in the ICBDSR surveillance program

<sup>c</sup> Excluding birth defect cases listed in the ICBDSR surveillance program